HLA B*15:02, Carbamazepine Sensitivity
Also known as: B1502, Carbamazepine Sensitivity, HLA B*1502, HLA B1502
Use
This test has been recommended for patients of Asian descent who are being considered for carbamazepine therapy. The utility of this test for patients of other ethnic backgrounds has not been established.
Special Instructions
Not provided.
Limitations
Even with strict collection and testing protocols, there is a chance that an occasional specimen may be unsuitable for testing. In those instances, an additional sample might be needed. It's important to note that the absence of the HLA B*15:02 allele does not entirely eliminate the risk of an adverse drug reaction. The test has not been cleared or approved by the FDA, and its utility outside of the Asian population has not been conclusively established.
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
LOINC Codes
- 57979-7 - HLA-B*15:02 Ql
- 49549-9 - Ref lab test method
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
7 mL whole blood
Container
Lavender-top (EDTA) tube
Storage Instructions
Maintain whole blood at room temperature or refrigerate.
Causes for Rejection
Hemolysis; clotted specimen; insufficient volume of DNA
Other tests from different labs that may be relevant